Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revatio in Chinese adults with pulmonary arterial hypertension
CTR20212771Phase 4Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sildenafil in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and Incidence of serious adverse events (SAEs) and death. Started Nov 2021; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20212771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212771.